Approval · Notice of Compliance 37982 · 2026
AA-MEDROXY: Notice of Compliance 37982
Issued July 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37982
- Date
- July 24, 2026
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Canadian reference product
- PROVERA (Pharmacia & Upjohn Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AA-MEDROXY | Not yet assigned | — |
Medicinal ingredients
- MEDROXYPROGESTERONE ACETATE 2.5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 10 MG per TAB
- MEDROXYPROGESTERONE ACETATE 100 MG per TAB